insiderwall
Menu
SuperinvestorInsider
Prime Medicine Inc. PRME

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Prime Medicine Inc. is a biotechnology company dedicated to developing one-time curative genetic therapies using its proprietary Prime Editing platform. This versatile, precise, and efficient gene editing technology enables targeted modifications at specific genomic sites without inducing double-strand DNA breaks, pote

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees146
TickerPRME

Statistics

Market Cap$562.6M
Revenue (TTM)$4.6M
Net Income-$201.1M
Net Margin-4342.4%
EPS$-1.35
P/E-2.09
P/S128.95
P/B6.78
EV/EBITDA-2.51
ROE-216.1%
Dividend Yield
Price$3.12

Data: Twelve Data · Revenue = mcap / P/S